PF-06651600 for the Treatment of Alopecia Areata
A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS
In the register
The register attaches this trial to Ritlecitinib (Litfulo) (Pfizer), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2/3
- Sponsor
- Pfizer
- Participants (registry)
- 718
- Start
- December 2018
- Primary completion
- December 2020
- Study completion
- June 2021
- Last registry update
- February 2022
- Countries
- United States, Argentina, Australia, Canada, Chile, China, Colombia, Czechia, Germany, Hungary, Japan, Mexico, Poland, Russia, South Korea, Spain, Taiwan, United Kingdom
Conditions studied: Alopecia Areata
Interventions: PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo
Other trials of Ritlecitinib (Litfulo)
- NCT05522556Available (expanded access)
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
- NCT07821216Active, not recruiting
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
- NCT07226531Completed
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
- NCT07152119Recruiting
A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
- NCT07200128Completed
A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings
- NCT06531109Active, not recruiting
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
- NCT06279221Active, not recruiting
Litfulo Capsules Special Investigation
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.